Search results
Results from the WOW.Com Content Network
Benign liver tumors generally develop on normal or fatty liver, are single or multiple (generally paucilocular), have distinct delineation, with increased echogenity (hemangiomas, benign focal nodular hyperplasia) or absent, with posterior acoustic enhancement effect (cysts), have distinct delineation (hydatid cyst), lack of vascularization or show a characteristic circulatory pattern ...
Suspicion of hepatomegaly indicates a thorough medical history and physical examination, wherein the latter typically includes an increased liver span. [citation needed] On abdominal ultrasonography, the liver can be measured by the maximum dimension on a sagittal plane view through the midclavicular line, which is normally up to 18 cm in ...
The cell of origin for this disease is an immature cytotoxic T-cell clonally expressing the γδ T-cell receptor.The disease is seen more often in immunosuppressed recipients of solid organ transplants, an association that has led to the hypothesis that long-term immune stimulation in the setting of immunosuppression is the causative agent.
Cavernous hemangiomas (also called hepatic hemangioma or liver hemangioma) are the most common type of benign liver tumor, found in 3%– 10% of people. [2] They are made up of blood clusters that are surrounded by endothelial cells. [5] These hemangiomas get their blood supply from the hepatic artery and its branches. [5]
A cavernous liver hemangioma or hepatic hemangioma is a benign tumor of the liver composed of large vascular spaces lined by monolayer hepatic endothelial cells. It is the most common benign liver tumour, and is usually asymptomatic and diagnosed incidentally on radiological imaging or during laparotomy for other intra-abdominal issues.
Focal nodular hyperplasia is a benign tumor of the liver (hepatic tumor), which is the second most prevalent tumor of the liver after hepatic hemangioma. [1] It is usually asymptomatic, rarely grows or bleeds, and has no malignant potential. [ 2 ]
FLC accounts for 1–10% of primary liver cancers. [24] It typically has a young age at presentation when compared to conventional HCC. Previously it was estimated to be 20–40 years, mean ages 27 years, [ 25 ] but when analysis is restricted to those patients who are confirmed with a molecular test to have FLC, the age range is 10-40 and mean ...
Liver function tests (LFTs or LFs), also referred to as a hepatic panel or liver panel, are groups of blood tests that provide information about the state of a patient's liver. [1] These tests include prothrombin time (PT/INR), activated partial thromboplastin time (aPTT), albumin , bilirubin (direct and indirect), and others.